Macular Edema (ME), Non Infectious Uveitis
Conditions
Keywords
Suprachoroidal Triamcinolone, Macular Edema, Non infectious uveitis, Subtenon resistant
Brief summary
The goal of this study is to learn if a suprachoroidal triamcinolone injection can treat vision-threatening swelling in the center of the retina (macular edema) caused by non-infectious uveitis, especially in people who did not improve after a standard steroid injection around the eye (sub-Tenon injection). The main questions it aims to answer are: Does vision improve on the eye chart after the injection? Does the injection lower retinal swelling (reduction in thickness) within 3 months? Participants will: Have a pre-treatment check (vision test, slit-lamp exam, and a retinal scan called OCT). Receive one suprachoroidal triamcinolone injection under anesthetics drops in a sterile setting (operating room) with standard monitoring. Return for visits about 1 month and 3 months after treatment for repeat vision tests, and OCT scans. Contact the clinic if they notice pain, redness, new floaters, or worsening vision.
Interventions
For suprachoroidal injection, we developed a custom-made delivery system to access the potential suprachoroidal space. A 1 mL tuberculin syringe fitted with a 27-gauge needle was prepared, and a plastic sleeve from a 24-26 G IV cannula was placed over the needle as a spacer to control penetration depth.
Sponsors
University of Baghdad
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Non-infectious uveitis complicated with macular edema * Uveitic macular edema of less than four months' duration * Macular edema persisted despite lack of intra-ocular inflammation * No response to posterior sub-Tenon triamcinolone acetonide injections
Exclusion criteria
* Those with epiretinal membrane-associated macular edema * Below 18 years
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Visual acuity improvement | 3 months | visual acuity improvement was defined as a gain of two or more lines in visual acuity or a reduction in logMAR values |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Central Macular Thickness | 3 Months | A reduction in central macular thickness (CMT) exceeding 20%. |
Countries
Iraq
Contacts
Primary ContactMohammed Suhail Al-Salam
Outcome results
None listed